학술논문
Clinical studies of sparfloxacin in the treatment of otorhinolaryngological infections tonsillitis and pharyngolaryngitis / 耳鼻咽喉科領域感染症に対するSparfloxacinの臨床評価
Document Type
Journal Article
Author
Akihiro UCHIZONO; Akira TOHNAI; Atsushi SHINKAWA; Ginichiro ICHIKAWA; Haruo ITO; Hideki OKAZAKI; Hideshige KIMURA; Hideyo ASAI; Hiroko ISAJI; Hirosato MIYAKE; Hiroshi WATANABE; Hiroshi YAMASHITA; Hitoshi OGINO; Junichiro SHIMADA; Katsuhiro HIRAKAWA; Kazuhiko GOTO; Keiko KANESADA; Kohichi DEGUCHI; Kohji AJISAKA; Kohji SERA; Kozo FUKAMI; Mamoru TSUDA; Masaru OHYAMA; Masashi WADA; Masayoshi OZAKI; Minoru ISHIDA; Mitsuaki INAGAKI; Naoya MIYAMOTO; Ototaka KAKI; Ryuji KIYOTA; Shunkichi BABA; Soichiro NAGATA; Syozo KAWAMURA; Takatsugu ITABASHI; Takatsugu KATAOKA; Takayuki SHIRAISHI; Takehiro KOBAYASHI; Takeshi MARUO; Tetsuya SHIMA; Tetsuyasu HIRATA; Tohru SEKITANI; Toru MATSUNAGA; Yasuo HARADA; Yasuo IWABUCHI; Yoichi MASUMITSU; Yutaka OGAWA; 三宅 浩郷; 世良 公志; 丸尾 猛; 伊佐治 広子; 伊藤 晴夫; 兼定 啓子; 内薗 明裕; 出口 浩一; 原田 康夫; 和田 昌士; 増満 洋一; 大山 勝; 宮本 直哉; 小川 裕; 小林 武弘; 尾崎 正義; 山下 裕司; 岡崎 英紀; 岩淵 康雄; 島 哲也; 島田 純一郎; 市川 銀一郎; 平川 勝洋; 平田 哲康; 後藤 和彦; 新川 敦; 木村 栄成; 東内 朗; 松永 亨; 板橋 隆嗣; 柿 音高; 永田 総一郎; 河村 正三; 津田 守; 浅井 英世; 深水 浩三; 清田 隆二; 渡辺 洋; 片岡 隆嗣; 白石 孝之; 石田 稔; 稲垣 光昭; 荻野 仁; 関谷 透; 馬場 駿吉; 鯵坂 孝二
Source
耳鼻と臨床 / jibi to rinsho. 1991, 37(5):949
Subject
Language
Japanese
ISSN
0447-7227
2185-1034
2185-1034
Abstract
Sparfloxacin (SPFX) was evaluated for its efficacy, safety and usefulness in the treatment of tonsillitis, pharyngolaryngitis and other infections.SPFX was administered orally in divided or single doses of 100mg to 300mg daily. The efficacy rate judged by the doctor in charge was 97.9% (47/48) in cases of tonsillitis, 92.3% (12/13) in cases of pharyngolar- yngitis, 100% in 14 cases of otitis externa and 100% in 4 cases of other diseases. The clinical efficacy judged by the trial committee in cases of tonsillitis was 83.3% (40/48).Bacteriological eradication rates were 97.5% (39/40 isolates) in gram-positive bacteria including S. aureus, S. pneumoniae, S. pyogenes, etc., 100% in 16 isolates of gram-negative bacteria including B. catarrhalls and H. influenzae and in 5 isolates of anaerobic bacteria.Side effects, mainly involving gastrointestinal symptoms, were observed in 4 of 87 cases (4.6%). In one case only, a clinical abnormality was detected, an elevated total bilirubin.In the those cases suitable for evaluation, the doctor in charge judged the drug to be useful in 91.4% (74/ 81) of patients treated.These results indicate that SPFX, in single or divided doses of 100mg to 200mg is useful in the treatment of otorhinolaryngological infections including tonsillitis, pharyngolaryngitis, otitis externa and acute suppurative parotitis.